HZNP Horizon Therapeutics Public Limited Company

30.76
-1.2  -4%
Previous Close 31.96
Open 32.51
Price To Book 2.68
Market Cap 5,849,194,346
Shares 190,155,863
Volume 2,546,702
Short Ratio
Av. Daily Volume 1,828,216
Stock charts supplied by TradingView

NewsSee all news

  1. Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline

    -- Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment -- -- Compelling Fit with

  2. TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes

    -- Data presented as part of ENDO 2020 demonstrates proptosis response regardless of age, gender and smoking status -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced new pooled efficacy data from the Phase 2

  3. Horizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it, in partnership with Illinois Governor JB Pritzker, has provided $500,000 to the Illinois COVID-19 Response Fund and $500,000 to the Illinois Biotechnology

  4. Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease

    – Recent Data Supports Urgent Need to Address Uric Acid Accumulation and Protect the Kidney– Horizon Therapeutics plc (NASDAQ:HZNP) today announced the launch of Down and Out Kidney, a campaign to highlight the

  5. Horizon and Willis Tower Elevate the Need for Rare Disease Innovation on Rare Disease Day

    Horizon Therapeutics (NASDAQ:HZNP) and Willis Towers Watson (NASDAQ:WLTW) are partnering with Willis Tower to light the antennas of the Willis Tower on Feb. 29 in recognition of Rare Disease Day and to raise awareness

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released December 8, 2016 - primary endpoint not met.
ACTIMMUNE
Friedreich's Ataxia (FA)
Phase 4 enrolment to be completed mid-2020.
Krystexxa with Methotrexate - MIRROR RCT
Gout
FDA Approval announced January 21, 2020.
Teprotumumab
Thyroid Eye Disease (TED)

Latest News

  1. Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline

    -- Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment -- -- Compelling Fit with

  2. TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes

    -- Data presented as part of ENDO 2020 demonstrates proptosis response regardless of age, gender and smoking status -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced new pooled efficacy data from the Phase 2

  3. Horizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it, in partnership with Illinois Governor JB Pritzker, has provided $500,000 to the Illinois COVID-19 Response Fund and $500,000 to the Illinois Biotechnology

  4. Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease

    – Recent Data Supports Urgent Need to Address Uric Acid Accumulation and Protect the Kidney– Horizon Therapeutics plc (NASDAQ:HZNP) today announced the launch of Down and Out Kidney, a campaign to highlight the

  5. Horizon and Willis Tower Elevate the Need for Rare Disease Innovation on Rare Disease Day

    Horizon Therapeutics (NASDAQ:HZNP) and Willis Towers Watson (NASDAQ:WLTW) are partnering with Willis Tower to light the antennas of the Willis Tower on Feb. 29 in recognition of Rare Disease Day and to raise awareness

  6. Horizon Therapeutics plc Partners with EveryLife Foundation to Establish $1 Million #RAREis Scholarship for Adults with Rare Diseases

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced a $1 million commitment over five years to establish the #RAREis scholarship, a program that will be made available by the EveryLife Foundation for Rare Diseases.

  7. Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2019 Financial Results; Announces Full-Year 2020 Guidance

    -- Record Fourth-Quarter 2019 Net Sales of $363.5 Million Driven by 14 Percent Growth in the Orphan and Rheumatology Segment; Fourth-Quarter 2019 GAAP Net Income of $592.8 Million; Adjusted EBITDA of $139.9 Million

  8. Horizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the Company will participate in the following conference in March: Cowen and Company 40th Annual Health Care Conference Date: Tuesday, Mar. 3,

  9. Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules

    -- Oral granules in packets provide an additional, tear-open option for people living with cystinosis -- Horizon Therapeutics plc (NASDAQ:HZNP) announced today that the U.S. Food and Drug Administration (FDA) has

  10. Uplifting Athletes Announces Horizon Therapeutics plc as Exclusive Sponsor to Help Tackle Rare Disease at the National Football League (NFL) Scouting Combine

    -- NFL Draft Prospects Participating in ‘Reps for Rare Disease' Will Help Raise Funds for Research and Awareness Programs -- -- Horizon will match Pledged Donations Through the Company's #RAREis Program -- Horizon

  11. Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2019 Financial Results and Host Webcast on Feb. 26, 2020

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that its fourth-quarter and full-year 2019 financial results will be released on Wednesday, Feb. 26, 2020. Following the announcement, Horizon's management will

  12. Horizon Therapeutics Announces Significant Expansion and Relocation of U.S. Operations

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it has agreed to purchase the three-building campus in Deerfield that formerly belonged to Takeda Pharmaceuticals. The transaction is expected to close in the

  13. Horizon Therapeutics plc Announces Changes in Research and Development Organization

    - Scott Brun, M.D. Named Senior R&D Advisor - Horizon Therapeutics plc (NASDAQ:HZNP) today announced changes to its research and development organization structure. Effective immediately, Elizabeth H.Z. Thompson,

  14. The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease

    -- Phase 3 trial achieved its primary endpoint and all secondary endpoints with marked improvement in key indicators of disease -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that The New England Journal of

  15. FDA Approves TEPEZZATM (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)

    -- First and only FDA-approved medicine for TED, a serious, progressive, vision-threatening rare disease -- -- Clinical improvements were seen as early as six weeks, with continued improvement across the 24-week

  16. Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs

    -- Increases KRYSTEXXA® (pegloticase injection) Peak U.S. Annual Net Sales Expectations to More Than $1 Billion -- -- Increases Teprotumumab Peak U.S. Annual Net Sales Expectations to More Than $1 Billion -- --

  17. MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate

    -- Seventy-Nine Percent of Patients Achieved a Complete Response -- -- New Data Continues to Support Immunomodulation Strategy to Improve Patient Outcomes -- Horizon Therapeutics plc (NASDAQ:HZNP) announced today

  18. FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)

    -- If approved, teprotumumab would be the first and only approved medicine for people living with TED, fulfilling a significant unmet need -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the Dermatologic

  19. Horizon Therapeutics plc Trading Halted Today; FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting to Discuss Teprotumumab for Thyroid Eye Disease

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that NASDAQ has halted trading of the Company's common stock. As per the U.S. Food and Drug Administration (FDA) guidelines for new molecular entities (NMEs), the

  20. Horizon Therapeutics plc to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the Company will participate in the 38th Annual J.P. Morgan Healthcare Conference. Timothy Walbert, chairman, president and chief executive officer will

  21. Horizon Therapeutics plc Opens New Manufacturing and R&D Facility in South San Francisco

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today the opening of its new office in South San Francisco, located at 2 Tower Place, 12th floor. The 20,000 square-foot facility will feature laboratory space that will

  22. Horizon Therapeutics plc Launches New Online Community Connecting People Living with Thyroid Eye Disease and Urging them to "Listen to Your Eyes"

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced the launch of "Listen to Your Eyes," a new website and Facebook community designed to provide education and support for people who are living with thyroid eye

  23. FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Workplaces for Parents List

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that it has been named to FORTUNE Magazine's 2019 "Best Workplaces for Parents" list, which highlights companies that best support employees, regardless of

  24. Horizon Therapeutics plc to Participate in Upcoming Investor Conferences

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the Company will participate in the following upcoming conferences: Stifel 2019 Healthcare Conference Date: Tuesday, Nov. 19, 2019 Presentation Time:

  25. Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes

    -- Horizon data at American College of Rheumatology Annual Meeting also cite the need for vigilance in treating gout among kidney transplant recipients -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced the

  26. The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace

    Horizon Therapeutics plc (NASDAQ:HZNP) has been awarded a Top Workplaces 2019 honor by the Chicago Tribune. This is the fifth consecutive year Horizon has received this honor. "We take tremendous pride in being named

  27. Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019

    - Research, interactive features and charitable opportunity support advancement of care - Horizon Therapeutics plc (NASDAQ:HZNP) will join the leading voices in the nephrology community this week to inform and build

  28. Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced an integrated analysis of efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab will be presented during an oral session at the American

  29. New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting

    -- Data to be presented from in-practice clinician case series on novel immunomodulation strategy -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced multiple presentations that will highlight the serious,

  30. Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced integrated, pooled efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab for the treatment of active thyroid eye disease (TED) compared to

  31. Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain's Chicago Business

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it is has been named one of the Most Innovative Companies in Chicago by Crain's Chicago Business, ranking number two. Crain's compiles the list based on a

  32. AVISE® MTX Test from Exagen Supports Horizon Therapeutics plc Clinical Trial to Evaluate Pegloticase with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout

    SAN DIEGO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), is pleased to announce clinical study support for Horizon Therapeutics plc (NASDAQ:HZNP) to measure methotrexate polyglutamates (MTXPGs), the

  33. New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid

  34. For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put "Vision First"

    -- Text the word "EYE" to 56512 to generate a donation from Horizon to Prevent Blindness to fund TED education -- Today, in support of World Sight Day, Horizon Therapeutics plc (NASDAQ:HZNP) and Prevent Blindness

  35. Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that its third-quarter 2019 financial results will be released on Wednesday, Nov. 6, 2019. Following the announcement, Horizon's management will host a live

  36. New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium

    Additional results from the Phase 3 confirmatory clinical trial (OPTIC) of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented at the American Society of Ophthalmic

  37. Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it has been named one of the top 100 adoption-friendly workplaces in the country by the Dave Thomas Foundation for Adoption, ranking number 56 overall and

  38. Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)

    -- If Approved, Teprotumumab Would be the First FDA-Approved Medicine for this Vision-Threatening Disease -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that the U.S. Food and Drug Administration (FDA) has

  39. Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer

    - Current Executive Vice President and Chief Business Officer, Robert F. Carey, will Retire Effective Oct. 1. - DUBLIN – August 28, 2019 – Horizon Therapeutics plc (NASDAQ:HZNP) today named Andy Pasternak executive